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Background: Mutations in SH2D1A/DSHP/SAP gene are responsible for the onset of X-linked lymphoproliferative disease 
type 1 (XLP1) that have increased risk for B-cell lymphoma development. In XLP1 patients SAP deficient NK, NKT and CD8+ 
cytotoxic T cells are inefficient in eliminating EBV-infected proliferating B cells that may partially contribute to the lymphoma 
development. However, little is known about impairment of B cell characteristics in XLP1. Aim: To analyze the cell surface phe-
notype and functional characteristics of EBV-transformed B-lymphoblastoid cell lines from XLP1 patients (XLP B-LCLs) in com-
parison with conventional B-lymphoblastoid cell lines (B-LCLs). Methods: Studies were performed on SAP-negative B-LCLs 
T5-1, 6.16, RPMI 1788; SAP-positive B-LCL MP-1 and XLP B-LCLs IARC 739, XLP-D, XLP-8005. Cell surface immuno-
phenotyping was performed using flow cytometry analysis. The level of apoptotic cells (Annexin V-binding), cell viability (MTT 
assay), and cell proliferation (trypan blue exclusion test) were evaluated in response to ligation of CD40, CD95, CD150 and IgM 
cell surface receptors. Results: A cell surface phenotype and functional features that distinguish XLP B-LCLs from conventional 
B-LCLs were revealed. XLP B-LCLs showed the upregulated level of CD20, CD38 and CD86 cell surface expression and down-
regulation of CD40, CD80 and CD150 expression. The major functional differences of XLP B-LCLs from conventional B-LCLs 
concern the modulation of CD95 apoptosis via CD40 and CD150 receptors and unresponsiveness to proliferative signals triggered 
by CD40 or colligation of BCR with CD150. Conclusion: The data suggest that the B-LCL from XLP1 patients have an intrinsic 
defect that affects cell activation, apoptosis, and proliferation.
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X-linked lymphoproliferative disease (XLP) be-
longs to X-linked genetically determined primary 
immunodeficiency syndromes that affect both in-
nate and adaptive immunity. XLP is characterized 
by severe immune dysregulation, often triggered 
by Epstein — Barr virus (EBV) infection, with clini-
cal manifestations that include fatal mononucleosis, 
hemophagocytic lymphohistiocytosis (HLH), B-cell 
lymphoproliferative disorder, B-cell lymphoma, and 
dysgammaglobulinemia [1–3]. XLP as rare inherited 
X-linked immune deficiency (Duncan’s disease) was 
first described by Purtilo et al. in 1975 [4], however 
the first report should be credited to Bar et al. present-
ing circumstantial evidence for the association of EBV 
infection with fulminating lymphoproliferative disease 
[5]. XLP affects from 1 to 3 million boys in the world, 
and usually develops in childhood or early adoles-
cence [6]. In response to EBV infection XLP patients 
develop a fulminant form of infectious mononucleosis 
with high rate of mortality. Uncontrolled proliferation 
of EBV infected B cells frequently results in severe lym-
phoproliferative illness with clinical features of fever, 
hepatosplenomegaly, lymphadenopathy, and pancy-
topenia. Clinical manifestations could be acute, like 
HLH or lymphoma, or less aggressive with recurrent 
infections and dysgammaglobulinemia. XLP patients 
often demonstrate more than one phenotype with 
tendency of progression to more aggressive disease 
manifestations [6].
The substantial progress in understanding the XLP 
pathophysiology was made with revealing the mo-
lecular basis of this immunodeficiency. First, the XLP 
gene was mapped to the Xq24–27 of the long 
arm of the X chromosome, and interstitial dele-
tion of Xq25 was described in a male with XLP [1, 
7]. And only in 1998 three groups reported muta-
tions in SH2D1A/DSHP gene that are responsible 
for XLP  [8–10]. More than 70 mutations in SH2D1A 
resulting in XLP have been reported to the Human 
Gene Mutation Database (HGMD), however they 
were found in 60–70% of XLP cases [1–3]. This 
stimulated the search for other genetic abnormalities 
in XLP. In 2006 it was found that mutations of BIRC4/
XIAP, encoding X-linked inhibitor of apoptosis (XIAP), 
were associated with XLP phenotypes [11]. Clinical 
entities linked to SH2D1A and XIAP deficiencies now 
are referred as XLP type 1 (XLP1) and type 2 (XLP2) 
respectively [1–3]. In addition, recessive mutations 
of autosomal genes encoding IL-2-inducible T cell 
kinase (ITK) [12, 13], CD27 [14], and Coronin 1A [15] 
are responsible for XLP-like syndromes with EBV-
associated lymphoproliferation.
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SH2D1A gene encodes the adaptor protein SH2 do-
main protein 1A (SH2D1A), also called Duncan’s di-
sease SH2-protein (DSHP) or SLAM-associated protein 
(SAP) [8–10]. This small 128 aa protein was first iden-
tified as an adaptor protein interacting with signaling 
lymphocyte activation molecule (SLAM)/CD150 [10]. 
It was demonstrated that SAP forms complexes with 
other members of SLAM family receptors by binding 
to conserved immunoreceptor tyrosine-based switch 
motif (ITSM) and recruiting Src-family kinases Fyn 
or Lyn [2, 16–18]. By interacting with SLAM family re-
ceptors, SAP is involved in regulation of T-cell help for 
germinal centers formation, development of NKT cells, 
cytotoxicity of CD8+ T lymphocytes and NK cells, and 
T-cell homeostasis mediated by reactivation-induced 
cell death (RICD) [19–23]. It becomes clear now that 
function of SH2D1A comprises different biological pro-
cesses and is much wider than regulation of signaling via 
SLAM family receptors. Besides ITSM, SAP was shown 
to bind also other tyrosine-based motifs. By direct in-
teraction with the first immunoreceptor tyrosine-based 
activation motif (ITAM) of CD3zeta chain, SAP plays 
a central role in the T cell activation [24]. In B cells SAP 
is able to bind immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) in FcgRIIb [17] and directly interacts 
with CD22, possibly also via ITIM [25].
Defects in T, NK and NKT functions and/or deve-
lopment upon SAP deficiency and limited information 
on expression and function of SAP in B cells contributed 
to the perception that XLP1 is a disease mainly medi-
ated by defective interactions between lymphocytes. 
 However this cannot account for all clinical manifesta-
tions in XLP, especially dysgammaglobulinemia and 
development of B cell lymphoma [6, 26, 27]. SAP was 
shown to be expressed in B cells in mouse spleen and 
germinal centers, subpopulation of human tonsillar 
B cells, few B-lymphoblastoid cell lines (B-LCLs), 
EBV-positive type I Burkitt lymphoma cell lines, Hodg-
kin’s lymphoma cell lines, and its expression could 
be induced by DNA damage in various cell lines of B-cell 
origin [17, 25, 28–33]. Moreover, it was shown that acti-
vation of endogenous wild type p53 in Burkitt lymphoma 
and B-lymphoblastoid cell lines induce SAP expres-
sion [33], and the fate of Burkitt lymphoma precursor 
cells is decided by the expression in B cells of the pro-
apoptotic SAP and EBV infection [34]. All these indicate 
that SAP is expressed at the narrow window of B cell 
differentiation, and SAP deficiency could also affect 
 B-cell maturation. To address the question whether 
B cells in patients with XLP1 have intrinsic defect, 
we studied EBV-transformed B-lymphoblastoid cell 
lines from XLP1 patients (XLP B-LCLs) in comparison 
with conventional B-LCLs. In the first report we focused 
on the cell surface phenotype and functional charac-
teristics, and the second report will cover cell signaling 
pathways and transcription factors expression profile.
MATERIALS AND METHODS
Cell lines and stimulation. Studies were per-
formed on EBV-transformed SAP-negative  B-LCLs 
T5–1, 6.16, RPMI 1788; SAP-positive B-LCL MP-1 (pro-
vided by Prof. E.A. Clark, USA); and EBV-transformed 
B-LCLs from XLP1 patients IARC 739 (interstitial 
deletion of SH2D1A), XLP-D (C→T mutation at posi-
tion 462), XLP-8005 (C→T mutation at position 471), 
kindly provided by Prof. K.E. Nichols (USA). Cell lines 
were maintained as previously described [30]. For 
cross-linking of surface receptors, we used the fol-
lowing monoclonal antibodies (mAbs): IPO-3 anti-
CD150 (IgG1) (IEPOR NANU); IPO-4 anti-CD95 (IgM) 
(IEPOR NANU); and G28–5 anti-CD40 (IgG1) (kind gift 
of Prof. E.A. Clark, USA). F(ab)’2 of goat anti-human 
IgM (Jackson ImmunoResearch Laboratories, Inc., 
USA) were used for IgM cross-linking on human B cell 
lines. Following final concentrations of antibodies were 
used: 0.5 mg/ml anti-CD40, 1.0 mg/ml anti-CD95, 
10.0 mg/ml anti-CD150, and 10.0 mg/ml anti-IgM.
Flow cytometry. Cell lines were immunophe-
notyped using standard immunofluorescent tech-
nique [30] and analyzed with EpicsXL fluorescent 
flow cyto meter (Beckman Coulter, USA). Following 
directly labeled monoclonal antibodies were used 
in this study: anti-IgD-PE and anti-CD23-FITC (Becton 
Dickinson, USA), anti-CD20-PE (Pharmingen, USA); 
anti-CD38-PE, anti-CD80-FITC and anti-CD86-PE (all 
from Immunotech, USA). The panel of monoclonal 
antibodies against CD27 (Becton Dickinson, USA), 
CD19 (clone CB19) (IEPOR NANU), anti-CD150 (clone 
IPO-3) (IEPOR NANU), anti-CD95 (clone IPO-4) (IEPOR 
NANU), anti-CD40 (clone G28–5) (kind gift of Prof. 
E.A. Clark, USA), and anti-IgM (DAKO, Denmark) were 
used in indirect immunofluorescent analysis with se-
condary FITC conjugated goat anti-mouse polyvalent 
Ig (Sigma, USA). Apoptotic cells were detected using 
an Annexin V-FITC apoptosis detection kit (Sigma, 
USA) according to manufacturer’s protocol. The data 
were analyzed using FCS Express 3 software (De Novo 
Software, USA).
Cell viability assay. The MTT assay was used 
to assess the cell viability. Cell lines were seeded 
at 1•104 cells per well in 96-well plates and treated 
with various combinations of monoclonal antibodies 
for 24 h and 48 h. Subsequently, 20 ml of stock solution 
(5 mg/ml) of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to each 
well. After incubation for 4 h at 37 °C, the multiwell 
plate was centrifuged to pellet formazan crystals, the 
medium was discarded, and 100 ml of DMSO was 
added to each well to dissolve the formazan crystals. 
The absorbance of formazan at 540 nm was measured 
by Labsystems Multiskan PLUS (USA). The mean 
of absorbance for 3 replicates from three independent 
experiments were used for statistical analysis. The cell 
viability is presented as a percentage ratio of absor-
bance of exposed cells to control cells.
Evaluation of cell proliferation. To assay for 
cell proliferation at 24 h and 48 h time points, each 
cell line was seeded at a density of 1•104 cells per 
100 ml in 96-well plate and incubated at 37 °C in tripli-
cates with 100 ml of media or with antibodies against 
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CD40, CD95, CD150, and IgM alone or in combina-
tions. Proliferation profiles were obtained by direct cell 
counting using trypan blue exclusion test.
RESULTS AND DISCUSSION
Characterization of cell surface phenotype of EBV-
transformed B-lymphoblastoid cell lines from XLP1 pa-
tients in comparison with B-LCLs was an initial step of our 
studies. B-LCLs T5-1, 6.16, RPMI 1788; MP-1 and 
EBV-transformed B-LCLs from XLP1 patients IARC 739, 
XLP-D, and XLP-8005 expressed B-lineage specific cell 
surface markers. While the level of CD19 cell surface 
expression was similar in all cell lines, XLP-LCLs had 
higher level of CD20 expression than B-LCLs (Fig. 1). 
For example, the mean of fluorescent intensity (MFI) 
for CD20 expression in XLP B-LCL IARC 739 reached 
356, in comparison with 89 and 70 in B-LCLs T5.1 and 
MP-1 respectively. All tested cell lines were IgM positive, 
however they were heterogeneous by IgD expression 
(see Fig. 1). XLP B-LCLs and B-LCLs had comparable 
levels of CD40, CD48, CD95, and CD150 expression; 
however CD40 and CD150 expression levels in XLP-
LCLs were slightly lower than in B-LCLs (see Fig. 1). 
In IARC 739 the MFI of CD40 and CD150 expression were 
115 and 62, whereas in T5-1 they were 150 and 138, and 
in MP-1 reached 220 and 156, respectively. In general, 
XLP B-LCLs and B-LCLs had similar levels of CD23 cell 
surface expression, with exception of B-LCL MP-1, 
which expresses SAP on protein level (see Fig. 1). XLP 
B-LCLs, as well as B-LCLs, did not express CD27 (data 
not shown). XLP B-LCLs were characterized by ele vated 
 levels of CD38 and CD86 cell surface expression in com-
parison with B-LCLs (see Fig. 1). As an illustration, the MFI 
of CD86 expression in IARC 739, T5-1 and MP-1 were 
1007, 403 and 411 respectively, so in XLP B-LCL it was 
more than twice higher (see Fig. 1). At the same time, 
in XLP-LCLs the expression level of CD80 was only slightly 
lower than in B-LCLs (see Fig. 1). Thus, XLP-LCLs have 
similar to B-LCLs expression levels of CD19, CD40, 
CD48, CD80, CD95, CD150 and IgM. However, we found 
elevated levels of CD20, CD38 and CD86 in EBV-trans-
formed B-lymphoblastoid cell lines from XLP1 patients. 
Since all tested cell lines had comparable level of CD40, 
CD95, CD150 and IgM cell surface expression, we tested 
how ligation of these receptor would affect apoptosis, 
proliferation and viability of XLP B-LCLs in comparison 
with conventional B-LCLs.
A number of cell surface receptors, especially 
 B-cell receptor (BCR) and members of TNFR  family 
Fig. 1. Cell surface phenotype of XLP B-LCL IARC 739 in compa rison with B-LCLs T5–1 (SAP-), and MP-1 (SAP+). Flow  cyto metry 
analysis
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are involved in regulation of cell survival during germi-
nal center reactions [35, 36]. Here we tested the level 
of sensitivity to CD95-mediated apoptosis and its modu-
lation via cell surface receptors in EBV-transformed 
 B-lymphoblastoid cell lines from XLP1 patients. All tested 
cell lines had comparable levels of sensiti vity to CD95-
mediated apoptosis induced with anti-CD95 antibody 
IPO-4 (IC50 ranging from 0.75 to 1.5 mg/ml). So, in all ex-
periments the concentration 1 μg/ml of anti-CD95 mAb 
was used for induction of apoptosis. After 8 hours 
of incubation with anti-CD95 mAb the levels of Annexin 
V-binding cells in all tested cell lines were in the range 
of 20–40%  (Fig. 2, a, b). 
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Fig. 2. Modulation of CD95-mediated apoptosis via CD40 and 
CD150 cell surface receptors. a — XLP B-LCLs IARC 739, 
 XLP-D and XLP-8005. b — B-LCLs MP-1 (SAP+) and SAP- B-LCLs 
RPMI 1788, 6.16 and T5–1. Percent of Annexin V-FITC binding 
cells after 8 hours of incubation with antibodies. Flow cytometry 
analysis. Data of four independent experiments are presented 
as the mean±SD. *p < 0.05, vs the effect of CD95 alone
It was previously shown that in B-LCLs derived 
from healthy individuals, as well as in EBV-positive 
Burkitt’s lymphoma cell lines Raji and BJAB, signals via 
CD40 and CD150 did not induce cell death, but modu-
lated CD95-mediated apoptosis [28]. Indeed, in either 
SAP+ (MP-1) or SAP- B-LCLs, CD40 ligation before of to-
gether with CD95 partially rescued cells from apoptosis 
(see Fig. 2, b). However, in XLP B-LCLs IARC-739 and 
XLP-D signals via CD40 were synergistic with CD95-
mediated apoptosis (p < 0.05) (see Fig. 2, a). CD150 and 
CD95 co-ligation augmented the number of apoptotic 
cells (compared to the effect of CD95 alone) in all tested 
B-LCLs derived from healthy individuals (p < 0.05) (see 
Fig. 2, b), but did not alter the level of CD95-induced 
apoptosis in XLP B-LCLs (see Fig. 2, a). Moreover, while 
combination of signals via CD40 and CD150 did not affect 
the level of CD95-mediated apoptosis in B-LCLs (see 
Fig. 2, b), in XLP B-LCLs CD150 ligation did not reduce 
synergistic effect of CD40 and CD95 (see Fig. 2, a). 
It should be noted that in cell line XLP-8005 neither 
CD40, nor CD150 cross-linking changed the amplitude 
of CD95-induced cell death (see Fig. 2, b). These ten-
dencies persisted for 24 and 48 h after cell stimulation, 
as accessed by cell viability (MTT test) and cell number 
in the cultures (Fig. 3, a, b). BCR (IgM) ligation practi-
cally did not change the number of cells in the culture 
of three tested cell lines, but reduced their viability (see 
Fig. 3, a, b). Signals via BCR, which in primary B cells 
protect from CD95-mediated apoptosis [37, 38], in EBV-
transformed B-LCLs were synergistic with CD95 that 
resulted in significant reduction of cell number and their 
viability (p < 0.05) (see Fig. 3, a, b). It should be noted 
that such synergistic effect was observed in XLP B-LCL 
IARC 739, as well as in SAP+ and SAP− B-LCL MP-1 and 
T5-1 (see Fig. 3, a, b).
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Fig. 3. Modulation of CD95-mediated apoptosis via CD40 and 
CD150 cell surface receptors in XLP B-LCL IARC 739 in comparison 
with B-LCLs T5-1 (SAP−), and MP-1 (SAP+) after 48 h of incuba-
tion with antibodies. a — cell viability (MTT assay, absorbance 
at 540 nm); b — cell number (trypan blue exclusion test). The data 
of three independent experiments are presented as a percent 
of control value (mean ± SD). *p < 0.05, vs the effect of CD95 alone
Since EBV-infected B-lymphocytes acquire proli-
ferative potential, we addressed the question whether 
signals via BCR, CD40 and CD150 may contribute 
to the proliferation of B-LCLs, including XLP1 derived 
cell line IARC 739. CD40 ligation resulted in prolifera-
tive effect in B-LCLs, however it significantly reduced 
the number of cells in XLP1 IARC 739 cell culture, and 
colligation with BCR did not change these tendencies 
(p < 0.05) (Fig. 4). CD150 ligation alone did not af-
fect cell proliferation, but diminished CD40-mediated 
signals in B-LCLs, but not in IARC 739 (see Fig. 4). 
At the same time, colligation of CD150 with BCR resulted 
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in strong proliferative effect in T5-1 cells, but slightly re-
duced cell numbers in MP-1 and IARC 739 cell cultures 
(p < 0.05) (see Fig. 4). Thus, the major distinct features 
of XLP B-LCLs are the modulation of CD95 apoptosis 
via CD40 receptor and unresponsiveness to prolifera-
tive signals triggered by CD40 or colligation of BCR with 
CD150.
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Fig. 4. Effect of CD40, CD150 and IgM cell surface ligation 
on the number of viable cells. XLP B-LCL IARC 739 is unrespon-
sive to proliferative signals triggered by CD40 or colligation BCR 
with CD150. The cell number (trypan blue exclusion test) in XLP 
B-LCL IARC 739 in comparison with B-LCLs T5-1 (SAP−), and 
MP-1 (SAP+). The data of three independent experiments are 
presented as a percent of control value (mean ± SD). *p < 0.05, 
compared to control; **p < 0.05, vs the effect of CD40 alone; 
***p < 0.01, as compared to control
EBV is a ubiquitous gamma-herpesvirus that 
latently infects > 90% of the world’s human popula-
tion. The primary targets of EBV are B lymphocytes, 
but EBV can also infect other cell types, including 
epithelial cells, monocytes and DCs [39, 40]. During 
primary infection, EBV infects resting B lymphocytes 
and expresses viral gene products driving prolifera-
tion of infected B cells. The ability of EBV to restrict 
expression of its genes allows the virus to persist 
in vivo within resting memory B cells and maintain 
a lifelong infection. Symptoms of EBV infection are 
typically mild and often indistinguishable from other 
mild common illnesses [39, 40]. However, EVB only 
seems to be an inoffensive virus. It was initially dis-
covered in a Burkitt’s lymphoma that had B-cell origin 
[34]. EBV, classified now by the WHO as a human 
DNA tumor virus, is associated with various malig-
nancies, such as Hodgkin’s and Burkitt’s lymphoma, 
life-threatening post-transplant lymphoproliferative 
disorders and nasopharyngeal carcinoma [34, 41]. 
Moreover, deletions or mutations in a small adaptor 
protein (SH2D1A/DSHP/SAP) diverts EBV infection 
from benign persistence to the acutely aggressive 
X-linked l ymphoproliferative disease (XLP1) that 
may rapidly kill the infected  individuals. Moreover, 
the risk for lymphoma development in XLP1 patients 
is increased  200-fold [34]. What are the cha llenging 
factors that so dramatically increased the rate 
of lymphoma development in XLP1 patients? From 
one side, in XLP1 patients SAP deficient NK, NKT 
and CD8+ cytotoxic T cells are inefficient in elimina-
tion of EBV-infected proliferating B cells that may 
contribute to the lymphoma development [2, 3, 42]. 
However, it is clear that several XLP1 clinical features 
are EBV independent, and lymphoma develop ment 
is documented both in EBV-positive and EBV-neg-
ative XLP1 patients [43–45]. This suggests that the 
absence of functional SAP has to affect the B cells 
as well. Our study pre sents the evidence of intrinsic 
defect in B-LCLs derived from XLP1 patients. We used 
the B-LCLs because EBV-transformed B cells are 
an important model for studying cellular transforma-
tion, especially B-LCLs from XLP1 patients, which 
have increased rate of B-cell lymphoma development. 
Immunopheno typing of B-LCLs revealed variations 
in surface expression of B-cell activation markers, 
especially upregulation of CD38 and CD86 expression 
in XLP B-LCLs. At the same time, the level of surface 
expression of IgM, CD40 and CD95 — the main recep-
tor regulators of B cell fate — was comparable in XLP 
B-LCLs and SAP− as well as SAP+ B-LCLs (see Fig. 1).
In vitro immortalization of B cells by EBV, which 
leads to the establishment of B-LCLs, is accom-
panied by the expression of a restricted set of viral 
genes, the so-called latency III program, coding for 
latent membrane proteins (LMP1, LMP2a, LMP2b), 
 Epstein — Barr nuclear antigens (EBNA1, 2, 3A, 3B, 
3C, LP), and small non-coding RNAs (EBERs) [34, 
40]. EBV infection, in particular LMP1, was shown 
to upregulate CD95 expression and to sensitize B cells 
to CD95-mediated apoptosis [46]. Indeed, all tested 
B-LCLs, including XLP B-LCLs, were sensitive to CD95-
initiated apoptosis (Fig. 2). However, we found the dif-
ferences in modulation of CD95-mediated apoptosis 
via cell surface receptors in XLP B-LCLs.
In normal B cell physiology, the CD40 receptor is one 
of the key regulators of B-cell activation and proliferation 
[47–49]. CD40 ligation in vitro triggers B-cell adhesion, 
sustained proliferation, and differentiation. The engage-
ment of CD40 on B cells by CD40L/CD154 is essential 
for initiation and progression of T-cell dependent hu-
moral immune response. CD40 is required for germinal 
center formation and progression, antibody isotype 
switching and affinity maturation that are crucial for 
the generation of memory B cells and long-lived plasma 
cells. CD40 signaling has been shown to protect im-
mature or mature B cells from BCR-mediated apopto-
sis [47]. In primary normal B cells CD40 ligation induces 
rapid and marked upregulation of CD95 expression 
and enhances sensitivity to CD95-mediated apoptosis, 
while BCR engagement rescues from apoptosis [48]. 
However, CD40 may play anti-apoptotic role by rescue 
from CD95-mediated apoptosis in EBV-transformed 
or malignant lymphocytes [50–52]. Indeed, in B-LCLs 
CD40 signals partially inhibited CD95-mediated 
apoptosis (see Fig. 2, b), but in XLP B-LCLs colligation 
of CD40 and CD95 enhanced apoptosis (Fig. 2, a). 
CD150 alone did not affect cell viability; however, 
CD150 and CD95 colligation elevated CD95-mediated 
apoptosis in B-LCLs. We did not reveal the peculiarities 
of XLP B-LCL in modulation of CD95 mediated signal-
ing via IgM: in all tested B-LCLs IgM colligation with 
CD95 significantly reduced cell number and  viability 
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(Fig. 3, a, b). Signals via CD40 alone exert a low 
proliferative effect and often are co-stimulatory with 
other stimuli [49]. We found that, in contrast to B-LCLs, 
CD40 ligation on IARC 739 XLP cells inhibited cell pro-
liferation; these cells were also unresponsive to proli-
ferative signals triggered by CD150 colligation with IgM 
(Fig. 4).
Taking together, our studies revealed cell surface 
phenotype and functional features that distinguish 
XLP B-LCLs from conventional B-LCLs. These include 
upregulation of CD20, CD38 and CD86 cell surface 
expression and slight downregulation of CD40, 
CD80 and CD150 expression. The major functional 
differences of XLP B-LCLs from conventional B-LCLs 
are in the modulation of CD95 apoptosis via CD40 and 
CD150 receptors and unresponsiveness to proliferative 
signals triggered by CD40 or colligation of BCR with 
CD150. Our subsequent paper will embrace some cell 
signaling studies that underlie functional peculiarities 
of XLP B-LCLs.
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